Key factors
sym | VTVT |
exch | US |
MCap | 58.51M |
Beta | 0.506 |
EPS | -9.71 |
Div date | 0000-00-00 |
Yesterday
sym | VTVT |
exch | US |
close | 24.74 |
50 Day MA | 14.66 |
200 Day MA | 17.87 |
52 Week High | 39.6 |
52 Week Low | 7.38 |
Target Price | 2.0 |
Market Cap Mln | 58.51 |
Share statistics
Shares Outstanding | 2432.86K |
Shares Float | 761.65K |
Percent Institutions | 16.05 |
PercentInsiders | 54.68 |
SharesShort | 57176 |
Short Ratio | 0.32 |
Shares Short Prior Month | 37974 |
Short Percent | 3.819 |
Income
Revenue TTM | 9000.0 |
Revenue Per Share TTM | 0.004 |
Gross Profit TTM | -9933.0K |
EBITDA | -25.4M |
Diluted Eps TTM | -9.71 |
earning
Earnings Share | -9.71 |
Dividend
Dividend Date | 0000-00-00 |
Last Split Date | 2023-11-21 |
Last Split Factor | 1:40 |
business
Enterprise Value Ebitda | -2.06 |
Enterprise Value Revenue | 3515.11 |
Book Value /share | -11.8 |
Price Sales TTM | 3631.36 |
ReturnOnAssetsTTM | -0.72 |
ReturnOnEquityTTM | -49.7 |
Sector
Gic Group | Pharmaceuticals, Biotechnology & Life Sciences |
Gic Industry | Biotechnology |
Gic Sector | Health Care |
Gic Sub Industry | Biotechnology |
Industry | Biotechnology |
Sector | Healthcare |
Codes
ISIN | US9183851057 |
CIK | 1641489 |
Code | VTVT |
CUSIP | 918385105 |
Employer Id Number | 47-3916571 |
CountryISO | US |
Currency Code | USD |
Currency Name | US Dollar |
Exchange | NASDAQ |
Currency Symbol | $ |
fund
Type | Common Stock |
UpdatedAt | 2024-04-05 |
Home Category | Domestic |
info
Fiscal Year End | December |
Full Time Employees | 16.0 |
IPODate | 2015-07-30 |
International Domestic | Domestic |
MostRecent Quarter | 2023-12-31 |
Contact
Name | vTv Therapeutics Inc |
Address | 3980 Premier Drive, High Point, NC, United States, 27265 |
Country Name | USA |
Phone | 336 841 0300 |
Web URL | https://vtvtherapeutics.com |
Logo URL | /img/logos/US/VTVT.png |
vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on the development of orally administered treatments for diabetes. The company's lead drug candidate is TTP399, an orally administered, small molecule, and liver-selective glucokinase activator for the treatment of type 1 diabetes; and HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases and psoriasis. It is also involved in the clinical development of other programs, including TTP273, an oral small molecule GLP-1 receptor agonist for postprandial glucose excursion to treat cystic fibrosis related diabetes; HPP3033, a non-electrophilic therapeutic approach to activating the Nrf2 pathway for the treatment of chronic diseases associated with oxidative stress; azeliragon, a RAGE antagonist for inflammatory lung diseases, including severe COVID-19, as well as for pancreatic and breast cancers; and HPP971, an Nrf2 activator. vTv Therapeutics Inc. has a license agreement with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including the compound HPP593; and license and research agreements with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.; Newsoara Biopharma Co., Ltd.; JDRF International; and Novo Nordisk A/S. The company was incorporated in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Incorporated.